CN Patent

CN114728933B — 5-ht2a受体抑制剂或反向激动剂及其制备方法和应用

Assigned to Shandong Luye Pharmaceutical Co Ltd · Expires 2023-06-16 · 3y expired

What this patent protects

本发明涉及一种作为5‑HT 2A 受体抑制剂或反向激动剂的新化合物及其制备方法和药物组合物。还涉及含有所述化合物或药物组合物在制备治疗5‑HT 2A 受体相关疾病的药物中的应用，所述疾病包括帕金森病引起的非运动症状：妄想、幻觉、抑郁、焦虑、认知障碍、睡眠障碍；痴呆相关的精神疾病；重度抑郁症；或精神分裂的阴性症状等。

USPTO Abstract

本发明涉及一种作为5‑HT 2A 受体抑制剂或反向激动剂的新化合物及其制备方法和药物组合物。还涉及含有所述化合物或药物组合物在制备治疗5‑HT 2A 受体相关疾病的药物中的应用，所述疾病包括帕金森病引起的非运动症状：妄想、幻觉、抑郁、焦虑、认知障碍、睡眠障碍；痴呆相关的精神疾病；重度抑郁症；或精神分裂的阴性症状等。

Drugs covered by this patent

pimavanserin-tartrate (PIMAVANSERIN TARTRATE)

Patent Metadata

Patent number: CN114728933B
Jurisdiction: CN
Classification: —
Expires: 2023-06-16
Drug substance claim: No
Drug product claim: No
Assignee: Shandong Luye Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.